A new clinical study with non-animal chondroitin sulfate Mythocondro® has just been released. The results highlight that a low dose supplementation with Mythocondro® has a demonstrated efficacy in the treatment of moderate knee osteoarthritis in obese subjects.
The study was specifically designed to associate Mythocondro® supplementation at low dose (600 mg per day) with a supervised physical activity after 2 weeks and 8 weeks (15 minutes cycling workout).
The results confirm the efficacy on all the joint health parameters like inflammation, pain and knee function (WOMAC Index) and resulted in significant reductions of body weight, Body Mass Index (BMI), , C-Reactive Protein (CRP), total cholesterol, Homeostatic Model Assessment of insulin resistance (HOMA-IR) and gamma- glutamyltransferase (GGT).
While the decreases in WOMAC and CRP levels had been already described in a previous clinical trial, the reduction in BMI, total cholesterol and HOMA observed here in Mythocondro® supplementation was never seen in human chondroitin sulfate trials before. Even if this result is likely to be primarily related to the increase in daily physical activity, probably due to decrease in inflammation, it may also bring to light the effect of Mythocondro® supplementation on metabolism.
The decrease in WOMAC score represents a reduction in the level of pain and an increase in joint functionality. The decrease in C-Reactive Proteins highlights an improvement in the systemic inflammation caused by osteoarthritis (OA).
Mythocondro® is the first Non-Animal chondroitin sulfate. Thanks to a patented biotransformation process, Mythocondro® provides a reliable and reproducible source of chondroitin. Mythocondro® offers a high quality and purity profile of chondroitin, an ingredient linked with superior joint health.